Adult acute myeloid leukaemia

Matthew Smith, Michael Barnett, Renato Bassan, Gemma Gatta, Carlo Tondini, Wolfgang Kern

Research output: Contribution to journalArticlepeer-review


The curability of acute myeloid leukaemia (AML) in a fraction of adult patients was demonstrated a long time ago. Currently, the probability of cure is consistently above fifty per cent in patients with de novo disease expressing favourable-risk associated cytogenetic features. Even better, the cure rate exceeds 75% in the acute promyelocytic subtype since the introduction of retinoic acid-containing regimens. In the meantime, continuing progress in supportive care systems and stem cell transplant procedures is making myeloablative therapies, when needed, somewhat less toxic - and thereby more effective - than in the recent past. Therefore, evidence is accumulating to indicate an improved therapeutic trend over the years, with the notable exception of older (>55 years) patients with adverse-risk chromosomal aberrations and/or leukemia secondary to myelodysplasia or prior cancer-related chemotherapy and/or radiotherapy. This review conveys the many facets of this progress, focusing on diagnostic subsets, risk classes, newer biological issues and conventional as well as innovative therapeutic interventions with or without autologous/allogeneic stem cell transplantation.

Original languageEnglish
Pages (from-to)197-222
Number of pages26
JournalCritical Reviews in Oncology/Hematology
Issue number3
Publication statusPublished - Jun 2004


  • Acute myeloid leukaemia (AML)
  • Diagnosis
  • Prognosis
  • Recommendations
  • Treatment

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Adult acute myeloid leukaemia'. Together they form a unique fingerprint.

Cite this